Close Menu

NEW YORK, Feb 1 – Large Scale Biology's fourth quarter revenues decreased slightly from a year ago, the company reported Thursday. LSBC attributed the drop in revenue, from $5.9 to $5.7 million, primarily to decreased development funding from Dow Chemical and Dow AgroSciences.

Higher R&D costs in the fourth quarter of 2000 compounded the drop in contract funding from Dow, the company said. Compared to the year-ago fourth quarter, R&D expenditures were up 87 percent to $4.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.